LIDORR CHEMICALS LTD - search results

United States - English - NLM (National Library of Medicine)

lidocaine hydrochloride- lidocaine gel

aidarex pharmaceuticals llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine hydrochloride usp is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of lidorx 3%. do not use lidorx 3% on traumatized mucosa or in the presence of secondary bacterial infection of the area of proposed application.

United States - English - NLM (National Library of Medicine)

lido rx- lidocaine gel

a-s medication solutions - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - anesthetic for relief of pain at site of injury; relief of musculoskeletal pain and soreness; pain from neuropathy; local medical procedures, injections and vaccines; relief of pruritis, pruritic eczema, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritis ani, pruritis vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. lidocaine hydrochloride usp is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of lidorx 3%. do not use lidorx 3% on traumatized mucosa or in the presence of secondary bacterial infection of the area of proposed application. teratogenic effects. pregnancy category b. reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caus

United States - English - NLM (National Library of Medicine)

lidocaine hydrochloride- lidocaine gel

lake erie medical dba quality care products llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine hydrochloride usp is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of lidorx 3%. do not use lidorx 3% on traumatized mucosa or in the presence of secondary bacterial infection of the area of proposed application.